Janssen gets priority review for prostate cancer combo; ImmunoGen reports Q1 Elahere sales
Janssen’s combination therapy of niraparib with abiraterone acetate plus prednisone for the treatment of BCRA-positive metastatic castration-resistant prostate cancer (mCRPC) is moving along.
Jannsen posted on Twitter on Friday morning that its submission to the FDA for the combination therapy has received a priority review. The drug combo was submitted for an NDA back in March.
UPDATE: Our submission to the U.S. FDA for a new targeted therapy for patients with BRCA-positive metastatic castration-resistant #ProstateCancer #mCRPC has received Priority Review. https://t.co/56gMkdGWQI https://t.co/UUmAs7ChdI
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.